Biophytis S.A. (BPTSY)

6,30 -1,70 (-21,25%) Al cierre: 09:30AM EDT

Biophytis S.A.

Sorbonne University
Bâtiment A 4ème étage 4 place Jussieu Cedex 05
Paris 75005
France
33 1 44 27 23 00
https://www.biophytis.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 22

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Stanislas Veillet Ph.D.	Chairman of the Board & CEO	374,55k	N/A	1965
Mr. Nicolas Fellmann	Chief Financial Officer	N/A	N/A	1968
Mr. Waly Dioh Ph.D.	Chief Clinical Operating Officer	N/A	N/A	1969
Dr. Pierre J. Dilda Ph.D.	Chief Scientific Officer	N/A	N/A	1970
Dr. Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	N/A	N/A	1946
Dr. Rob van Maanen FFPM, M.B.A., M.D.	Chief Medical Officer	N/A	N/A	1971
Mr. Edouard Bieth	Chief Business Officer	N/A	N/A	1980
Ms. Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	N/A	N/A	N/A
Ms. _ Teylan	Financial Controller	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Gobierno corporativo

El ISS Governance QualityScore de Biophytis S.A., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.